v. 20 – Q4 2021
|Market Executive Summary||
Major Development: Implementation for Track and Trace for export of drug formulations with regard to maintaining Parent-Child relationships in packaging levels and its uploading to the Central Portal, IVEDA has been extended from 01 Apr 2021 to 01 Apr 2022 for both SSI (small scale industry) and non-SSI manufacturers.
Phased implementation, starting with 2D coding through consolidation on GS1 standards to serialisation and traceability based on Gvt DB: “IVEDA” (formerly “DAVA”) for all medicines exported from India.
DAVA Portal is being replaced by IVEDA Portal. This means pharmaceutical exporters in India will now have to implement the Track and Trace system for maintaining the parent-child relationship in packaging levels and its uploading on the Central (IVEDA) portal from 01 April 2021.
While generally aligned to GS1 standards, recently the inclusion of QR codes outside the GS1 standard have been in discussion. See Note 9 for related links.
The Beta Version of IVEDA web portal (which will be replacing the DAVA portal) was launched on June 24, 2020. It is live now (in Beta version) at www.iveda-india.in and available to companies for data upload until 25 July 2020.
The processes for Company Registration, Excel to XML conversion, Bulk Data Upload, Serialization etc., are available in the User Manual.
The data pertaining to all export consignments starting from June 1, 2020 pertaining to finished drug formulations must be uploaded to the Beta version of the IVEDA portal, and subsequently on the final version.
DGFT Notification (Notification No. 13/2015-2020): The prohibition on the export of hydroxychloroquine and formulations that are made from hydroxychloroquine has been lifted as of June 18, 2020.